Skip to main content
Figure 1 | Molecular Cancer

Figure 1

From: Gene therapy for colorectal cancer by an oncolytic adenovirus that targets loss of the insulin-like growth factor 2 imprinting system

Figure 1

Construction and expression characterization of Ad315-E1A and Ad315-EGFP in cell lines with different IGF2 imprinting status. (a) In IGF2 MOI cell lines, CTCF binding factors are bound to DMD sites and the enhancer cannot control the H19 promoter, resulting in no expression of E1A or EGFP. (b) In IGF2 LOI cell lines, H19 has promoter activity that initiates expression of the downstream sequence due to CTCF complex regression. ITR: inverted terminal repeats.

Back to article page

Molecular Cancer

ISSN: 1476-4598